Emma Walmsley, GSK CEO (Fang Zhe/Xinhua/Alamy Live News)
November 17, 2022 08:01 AM ESTUpdated 11:33 AM
Deals
Cell/Gene Tx

GSK's cell ther­a­py re­treat hits an­oth­er part­ner as drug­mak­er ex­its Im­mat­ics col­lab­o­ra­tion

Amber Tong

It turns out that GSK’s broad re­treat from cell ther­a­pies went even deep­er than it let on.

As Im­mat­ics, which scored $50 mil­lion up­front …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times